MANALAPAN, N.J., April 8, 2019 /PRNewswire/ -- Armas Pharmaceuticals, Inc. is pleased to announce the release of its second and third generic products, Capecitabine and Imatinib, for the U.S. market. These products will be the first oral solid oncology products for Armas. Capecitabine will be available in strengths of 150 mg and 500 mg and Imatinib will be available in strengths of 100 mg and 400 mg.
"Following the launch of our first oncology injectable, Azacitidine for injection, in late 2018, Armas Pharmaceuticals is excited to announce the launch of our first two oral oncology products to the market. Imatinib and Capecitabine expands on Armas's goal to bring high quality, affordable pharmaceuticals to the US market," says John Niemi, President & CEO of Armas.
Capecitabine, an AB-rated generic equivalent to the brand Xeloda® (a trademark of Hoffman-La Roche, Inc), generated annual sales of approximately $108 million with the year ending December 31, 2018, according to sales data. Imatinib Mesylate, an AB-rated generic equivalent to the brand Gleevec® (a trademark of Novartis AG Corporation), generated annual sales of approximately $655 million with the year ending December 31, 2018, according to industry sales data.
About Armas Pharmaceuticals, Inc.
Armas Pharmaceuticals is a generic pharmaceutical company delivering an ever-growing portfolio of high-quality products that provide convenience, affordability and consistency. Through the development of strong partnerships and industry relationships, Armas maintains this pipeline of products with customer and patient satisfaction in mind. Headquartered in Manalapan, New Jersey, Armas Pharmaceuticals is always open to new partnership opportunities and ways to offer our customers the best products at affordable prices. For more information, please visit ArmasPharmaceuticals.com.
John Niemi, President & CEO
SOURCE Armas Pharmaceuticals, Inc.